Foghorn Therapeutics (FHTX) Stock Forecast & Price Target

Foghorn Therapeutics is viewed constructively because its preclinical EP300 degraders have shown better efficacy and safety than inobrodib, including tumor regression and complete responses in resistant models with improved platelet preservation. Although the Lilly-partnered FHD-909 program was discontinued after Phase 1 dose escalation failed to show sufficient efficacy in SMARCA2/4-mutant cancers, the favorable safety profile still supports proof-of-concept for Foghorn’s selective-targeting platform. The company is also narrowing focus through a ~40% workforce reduction, ~$168M of cash at Q2:26, and expected runway into H2:29, giving it time to advance wholly owned programs toward an IND expected in late 2027 and early clinical data in 1H29.

Foghorn Therapeutics is facing a weakened fundamental outlook because FHD-909, despite favorable safety and target engagement, failed to show the efficacy needed to support dose expansion, undermining the company’s only clinical-stage asset and casting doubt on SMARCA2/4 synthetic lethality as a viable strategy. The wind-down of the Lilly collaboration removes a major partnered value driver, while the selective SMARCA2 degrader will not advance and the remaining pipeline is fully preclinical, leaving the thesis dependent on assets not expected to be IND-ready until late ’27. Although a ~40% workforce reduction extends runway into H2:29, the lack of near-term clinical validation, the need for additional capital or a partner for EP300, and indefinite delays in the CBP program justify a cautious stance.